Key facts
- This page summarizes Merck KGaA's Form 4 filing for Xilio Therapeutics, Inc. (XLO).
- 4 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 26 Oct 2021, 17:06.
Merck KGaA - 26 Oct 2021 Form 4 Insider Report for Xilio Therapeutics, Inc. (XLO)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- XLO
- Reported as of
- 26 Oct 2021
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 26 Oct 2021, 17:06:33 UTC
- Prior SEC filing
- 21 Oct 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Christian Uhrich, Authorized signatory of Merck KGaA, Darmstadt, Germany
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Merck KGaA filed Form 4 for Xilio Therapeutics, Inc. (XLO) on 26 Oct 2021.
Change
- Previous filing in this sequence was filed on 21 Oct 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
XLO
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +416,060
- Change %
- Price
- Shares after
- 416,060
- Date
- 26 Oct 2021
- Ownership
- See Footnote
- Footnotes
- F1, F2
XLO
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +264,765
- Change %
- +64%
- Price
- Shares after
- 680,825
- Date
- 26 Oct 2021
- Ownership
- See Footnote
- Footnotes
- F2, F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
XLO
transaction
Derivative
Series B Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -3,952,568
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 26 Oct 2021
- Ownership
- See Footnote
- Underlying class
- Common Stock
- Underlying amount
- 416,060
- Exercise price
- Footnotes
- F1, F2
XLO
transaction
Derivative
Series C Preferred Srock
Conversion of derivative security
- Transaction value
- Shares
- -2,515,271
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 26 Oct 2021
- Ownership
- See Footnote
- Underlying class
- Common Stock
- Underlying amount
- 264,765
- Exercise price
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Merck KGaA is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 3 footnotes
Footnote F1
The Series B Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on a 9.5:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date.
Footnote F2
The shares are held directly by Merck Ventures B.V. Merck Ventures B.V. is a wholly owned indirect subsidiary of Merck KGaA, a publicly traded company. Merck KGaA may be deemed to have sole voting and dispositive power with respect to the shares held by Merck Ventures B.V.
Footnote F3
The Series C Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on a 9.5:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series C Preferred Stock had no expiration date.